Global Blood Therapeutics, Inc. (GBT) Financials

NASDAQ Currency in USD Disclaimer

$68.49

north_east NA Past Year
Day's range
$68.47
Day's range
$68.49
$200M$200M$100M$100M$0$0-$100M-$100M-$200M-$200M-$300M-$300M-$400M-$400MEarning201520152016201620172017201820182019201920202020202120210%0%-5000%-5000%-10000%-10000%-15000%-15000%-20000%-20000%-25000%-25000%-30000%-30000%Profit Margin
Profit Margin
Revenue
Earnings

GBT Income statement / Annual

Last year (2021), Global Blood Therapeutics, Inc.'s total revenue was $194.75 M, an increase of 57.31% from the previous year. In 2021, Global Blood Therapeutics, Inc.'s net income was -$303.09 M. See Global Blood Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014 FY-2013
Period Ended 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014 12/31/2013
Operating Revenue $194.75 M $123.80 M $2.11 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Cost of Revenue $3.32 M $1.99 M $48,000.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Gross Profit $191.43 M $121.82 M $2.06 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Gross Profit Ratio 0.98 0.98 0.98 0 0 0 0 0 0
Research and Development Expenses $212.14 M $155.12 M $174.56 M $131.31 M $87.81 M $61.21 M $36.66 M $16.32 M $12.86 M
General & Administrative Expenses $0.00 $0.00 $117.09 M $51.44 M $31.44 M $21.92 M $9.67 M $3.86 M $2.31 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $266.99 M $210.85 M $117.09 M $51.44 M $31.44 M $21.92 M $9.67 M $3.86 M $2.31 M
Other Expenses $0.00 $210.85 M $0.00 $0.00 $0.00 $0.00 $65,000.00 $0.00 $0.00
Operating Expenses $479.12 M $365.97 M $291.64 M $182.74 M $119.25 M $83.13 M $46.39 M $20.18 M $15.16 M
Cost And Expenses $482.44 M $367.96 M $291.69 M $182.74 M $119.25 M $83.13 M $46.39 M $20.51 M $15.66 M
Interest Income $720,000.00 $5.83 M $0.00 $0.00 $0.00 $0.00 $33,000.00 $1,000.00 $2,000.00
Interest Expense $15.47 M $9.81 M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Depreciation & Amortization $8.62 M $10.82 M $9.93 M $4.61 M $1.66 M $1.24 M $873,000.00 $666,000.00 $534,000.00
EBITDA -$278.53 M -$226.92 M -$256.83 M -$169.59 M -$115.37 M -$81.23 M -$45.49 M -$20.14 M -$17.58 M
EBITDA Ratio -1.43 -1.83 -121.84 0 0 0 0 0 0
Operating Income Ratio -1.47 -1.96 -133.44 0 0 0 0 0 0
Total Other Income/Expenses Net -$15.47 M -$4.38 M $14.52 M $8.55 M $2.22 M $659,000.00 $33,000.00 -$296,000.00 -$2.45 M
Income Before Tax -$302.61 M -$247.55 M -$266.77 M -$174.19 M -$117.02 M -$82.47 M -$46.36 M -$20.81 M -$18.12 M
Income Before Tax Ratio -1.55 -2 -126.55 0 0 0 0 0 0
Income Tax Expense $477,000.00 $5.43 M $14.52 M $8.55 M $2.22 M $659,000.00 $33,000.00 -$296,000.00 -$2.45 M
Net Income -$303.09 M -$247.55 M -$266.77 M -$174.19 M -$117.02 M -$82.47 M -$46.36 M -$20.81 M -$18.12 M
Net Income Ratio -1.56 -2 -126.55 0 0 0 0 0 0
EPS -4.82 -4.04 -4.57 -3.41 -2.76 -2.48 -3.62 -1.51 -0.83
EPS Diluted -4.82 -4.04 -4.57 -3.41 -2.76 -2.48 -3.62 -1.51 -0.83
Weighted Average Shares Out $62.93 M $61.33 M $58.32 M $51.15 M $42.32 M $33.21 M $12.81 M $13.76 M $21.80 M
Weighted Average Shares Out Diluted $62.93 M $61.33 M $58.32 M $51.15 M $42.32 M $33.21 M $12.81 M $13.76 M $21.80 M
Link